8-K: Assembly Biosciences Announces Positive Interim Results for Hepatitis B Drug Candidate ABI-4334

Assembly Biosciences reported encouraging interim results from a Phase 1b trial of its hepatitis B drug candidate, ABI-4334, showing strong antiviral activity and a favorable safety profile.

Summary

• Assembly Biosciences has released interim results from its Phase 1b clinical trial of ABI-4334, a next-generation capsid assembly modulator for chronic hepatitis B.
• The study evaluated two dose cohorts, 150mg and 400mg, with the 150mg cohort showing a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days.
• In a subset of participants with detectable HBV RNA, a mean decline of 2.5 log10 U/mL for HBV RNA was observed.
• The drug was well-tolerated with a favorable safety profile, and its half-life supports once-daily oral dosing.
• The 400mg cohort is still enrolling, with data expected in the first half of 2025.
• Gilead Sciences has an option to further develop and commercialize ABI-4334 after the completion of this Phase 1b study.

Sentiment

Score: 8

Explanation: The document presents positive interim results with strong antiviral activity and a favorable safety profile, suggesting a promising outlook for the drug candidate. However, it is still early-stage data, and there are risks associated with clinical trials.

Positives

• The drug demonstrated strong antiviral activity in the first cohort.
• The safety profile of ABI-4334 was favorable, with no serious adverse events.
• The drug's half-life supports convenient once-daily oral dosing.
• The observed antiviral activity is consistent with preclinical data.
• The drug achieved high clinical exposures relative to the required levels for antiviral activity.

Negatives

• Limited changes in viral antigens were observed over the 28-day treatment period, which was expected.
• Two grade three lab abnormalities were observed, but they resolved with continued dosing.

Risks

• The study is still ongoing, and the results are interim.
• The 400mg cohort data is not yet available.
• Gilead's option to further develop the drug is not guaranteed.
• Clinical and nonclinical data may not warrant further development of the product.
• Results of nonclinical studies may not be representative of disease behavior in a clinical setting.

Future Outlook

The company anticipates releasing data from the 400mg cohort in the first half of 2025 and will submit complete data from the trial for presentation at future scientific meetings. Gilead has an option to further develop and commercialize ABI-4334 after the completion of this Phase 1b study.

Management Comments

• Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio, stated that they are pleased to see strong antiviral activity in the first Phase 1b cohort.
• Management believes the interim data reinforces the potential of ABI-4334 to achieve their target clinical profile.

Industry Context

The development of new treatments for chronic hepatitis B is a significant area of focus in the pharmaceutical industry, with several companies working on novel therapies. Assembly Bio's results are being closely watched as they represent a potential advancement in the field.

Comparison to Industry Standards

• The 2.9 log reduction in HBV DNA is a strong result compared to some other early-stage HBV drug candidates.
• Gilead Sciences is a major player in the HBV space, and their option to acquire ABI-4334 highlights the potential value of the drug.
• Other companies such as Vir Biotechnology and Arbutus Biopharma are also developing novel HBV therapies, and the results of this trial will be compared to their progress.

Stakeholder Impact

• Shareholders may react positively to the encouraging interim results.
• Patients with chronic hepatitis B may benefit from the development of this new treatment.
• Employees of Assembly Bio may be motivated by the positive progress of the clinical trial.
• Gilead Sciences may see this as a promising opportunity for their HBV portfolio.

Next Steps

• Enrollment in the 400mg cohort is ongoing.
• Data from the 400mg cohort is expected in the first half of 2025.
• Assembly Bio expects to submit complete data from the trial for presentation at future scientific meetings.
• Gilead will evaluate the data package to decide on exercising their option for further development and commercialization.

Key Dates

Keywords

Hepatitis B, ABI-4334, Capsid Assembly Modulator, Antiviral, Clinical Trial, Phase 1b, HBV DNA, HBV RNA, Gilead Sciences, Chronic Hepatitis B